<?xml version="1.0" encoding="UTF-8"?>
<p id="Par45">Second, some approaches to regulatory and quality compliance that reflect the ‘need for speed’ during a pandemic outbreak also reduce development times. Highly abbreviated toxicology studies would likely shift the critical path back to CMC. Accepting business (but not product safety) risks — including cGMP processing at risk before cell bank testing is complete, conducting minimal product quality release testing, employing modular viral clearance, and conducting a rolling IND filing — would likely also contribute to accelerating the overall timeline.</p>
